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ABSTRACT Pooled polyvalent sera from lepromatous lep-
rosy patients were used to screen a Agtll recombinant DNA
expression library of Mycobacterium leprae in order to identify
the relevant antigens recognized by the human immune re-
sponse. Of the 300,000 phages screened, 4 clones were identi-
fied that coded for fusion proteins of the same molecular mass.
The fusion protein from clone LSR2 was tested for immuno-
reactivity in assays using peripheral blood cells and sera from
11 laboratory personnel and 105 patients across the leprosy
spectrum. LSR2 protein appears to be predominantly a T-cell
antigen. It evokes similar lymphoproliferative responses as the
native bacillus both at the individual level and in the leprosy
spectrum as a whole. Though only 50% of patient sera with
anti-M. leprae antibodies reacted with the fusion protein, the
pattern of reactivity in the antibody responses was also similar
for the various clinical types. The coding regions of clones
LSR1 and LSR2 are identical. They show no homology with
sequences stored in data banks and encode a protein of 89
amino acids with a calculated molecular mass of -10 kDa.
Leprosy is a chronic infectious disease caused by nonculti-
vable Mycobacterium leprae. The clinicopathological spec-
trum observed in this disease reflects the variability in the
host immune responses to the pathogen (1). Protective im-
munity is mainly effected by cellular responses as evidenced
by the presence of optimal T-cell functions in the localized
paucibacillary form of tuberculoid (TT) leprosy. In contrast,
the generalized multibacillary lepromatous (LL) leprosy
shows antigen-specific T-cell anergy concomitant with the
presence of high levels of specific and crossreactive myco-
bacterial antibodies (2, 3). Young et al. (4) constructed a
genomic library of M. leprae in the Agtll expression vector.
By using monoclonal antibodies (mAbs) as screening re-
agents, genes coding for 12-, 18-, 28-, 36-, and 65-kDa
proteins of M. leprae were identified. Whereas some ofthese
have been shown to share homology with the heat shock
proteins ofvarious species (5-8), the 18-kDa protein has been
found to be stimulatory for human T helper clones (9) and for
peripheral blood cells from healthy contacts (10).
With a view to identifying genes expressing proteins rec-
ognized by the human immune response to natural M. leprae
infection, we have used polyclonal antibodies obtained from
pooled sera of lepromatous patients to screen the Agtll DNA
expression library. We have identified four clones coding for
a fusion protein of the same molecular mass.§ It appears to
be a dominant T-cell antigen and mimics the native bacillus
in lymphoproliferative responses of all clinical types of
leprosy patients. It is also recognized by the sera of 50-70o
of the patients having anti-M. leprae antibodies.
MATERIALS AND METHODS
Subjects. The study included 105 leprosy patients attending
the Hansen disease clinic of Safdarjung Hospital (New Delhi)
and 11 healthy laboratory personnel with >3 years of con-
stant contact with patients. The type of leprosy was diag-
nosed on the basis of clinical and histopathological criteria of
Ridley and Jopling (11), and the bacterial index was assessed
by slit skin smears. Patients were bled prior to or within 6
months of treatment with a multidrug regimen consisting of
600 mg of rifampicin monthly, 100 mg of clofazimine on
alternate days, and 100 mg of dapsone daily.
Sera. Sera from untreated LL patients were screened for
the presence of anti-M. leprae antibodies by a dot ELISA
using sonicated M. leprae as antigen [leprosin, 10 ,g/ml;
courtesy of R. J. W. Rees through the Immunology of Lep-
rosy (IMMLEP) Program of the World Health Organization
(WHO)]. Ten sera showing strong reactivity with 10- and
20-ng dots of leprosin were pooled. Horseradish peroxidase-
conjugated anti-human IgG (1:200 dilution, Dakopatts, Den-
mark) and 4-chloro-1-naphthol (Sigma) were used for detec-
tion. The LL serum pool was depleted of anti-Escherichia
coli antibodies by adsorption with lysates of E. coli Y1083
lysogenized with Agtll, immobilized on nitrocellulose paper
(NCP). This serum pool was stored at -20°C and used at
1:200 dilution for screening the M. leprae DNA library.
Screening of Agtll M. leprae DNA Expression Library. The
Agtll M. leprae DNA library (courtesy of R. A. Young
through the IMMLEP Program ofWHO) was screened with
the above pool of preadsorbed LL sera (12). The positive
clones, designated LSR, were purified and checked for
crossreactivity with murine mAbsMC 2404, 0401, 1723, 2009,
4243, 4220 (obtained from WHO; ref. 13), and SA2D 7C
(courtesy of D. B. Young, Medical Research Council Unit,
Hammersmith Hospital, London; ref. 14), defining epitopes
on the 65-kDa antigen, and MC 8026 (WHO), defining the
18-kDa antigen of M. leprae.
Characterization of the Recombinant LSR Proteins. Lyso-
gens of LSR clones were established in E. coli Y1089 and
induced to produce recombinant proteins, as described (12).
Lysates thus obtained were subjected to SDS/8% PAGE (15)
followed by Western blot analysis (16) using the pooled LL
sera or anti-f3-galactosidase mAb (Promega).
DNA Hybridization. Samples (2 ,ul) of the phage stocks of
LSR clones, the five clones (Y3164, Y3178, Y3179, Y3180,
and Y3184 previously identified by using anti-M. leprae
Abbreviations: mAb, monoclonal antibody; WHO, World Health
Organization; NCP, nitrocellulose paper; PBMC, peripheral blood
mononuclear cell; LL, lepromatous; BL, borderline lepromatous;
BB, borderline; BT, borderline tuberculoid; TT, tuberculoid.
tTo whom reprint requests should be addressed.
§The sequence reported in this paper has been deposited in the
GenBank data base (accession no. X53487).
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murine mAbs (courtesy of R. A. Young) that define the 28-,
65-, 18-, 36-, and 12-kDa antigens, respectively, and Agtll
(without insert) were grown on a lawn of E. coli Y1090.
Bacteriophage DNA was transferred onto NCP, denatured
(1.5 M NaCl/0.5 M NaOH), and neutralized (1.5 M NaCl/0.5
M Tris-HCI, pH 8.0), and the dried filters were baked at 80'C
for 2 hr. Phage DNA from the above clones was cut with
EcoRI (New England Biolabs), and the fragments were
separated by electrophoresis in 0.8% agarose gel (type 2,
Sigma) and subjected to Southern blot analysis (17).
Purified and nick-translated insert DNA from clone LSR2
was used to probe the plaque replica and the Southern blot.
Hybridizations were carried out at 420C for 16 hr in 50%
(vol/vol) formamide/5 x SSC (lx SSC is 150 mM NaCl/15
mM trisodium citrate)/0.1% Ficoll/0.1% polyvinylpyrroli-
done/0.1% bovine serum albumin/50 mM Tris HCI, pH 7.5,
containing sonicated salmon sperm DNA at 250 gg/ml.
Washing was done sequentially in 2x SSC/0.1% SDS for 20
min, with two changes, at room temperature, followed by 2x
SSC/0.1% SDS at 500C for 30 min and finally 0.1 x SSC/0.1%
SDS at 64°C for 30 min. The blots were then exposed to
polyester x-ray films (Hindustan Photo Films Manufacturing,
Udhagamandalan, India) for 16 hr at -70°C.
M. leprae Antigens. Armadillo-derived M. leprae (courtesy
of R. J. W. Rees through the IMMLEP Program of WHO)
was used as integral and sonicated form for the lymphopro-
liferation assay and dot ELISA, respectively. Except where
stated 5 x 106 bacilli per ml and 10 and 20 ng of leprosin were
used. The expressed recombinant proteins were isolated
from lysates of E. coli Y1089 lysogenized with LSR2 and
tested at concentrations indicated below. Thirty microliters
of lysate (1 mg/ml) of LSR2 lysogen was resolved by SDS/
PAGE and transferred to NCP. The fusion protein band
identified in a position complementary to the Western blot
was cut out and converted into antigen-bearing particles by
dissolution in dimethyl sulfoxide, precipitation with carbon-
ate/bicarbonate buffer (pH 9.6), and resuspension in 1 ml of
medium RPMI 1640 (GIBCO) (18). A P3-galactosidase band,
obtained from lysates of E. coli Y1089 lysogenized with
Agtll, and a piece of NCP of similar size were treated in an
identical manner for use as controls.
Lymphoproliferation Assays. Ficoll/Hypaque-separated
(19) peripheral blood mononuclear cells (PBMCs) obtained
from 8 healthy contacts and from 15 tuberculoid-borderline
tuberculoid (TT-BT), 3 borderline (BB), and 15 borderline
lepromatous-lepromatous (BL-LL) patients were resus-
pended in RPMI 1640 containing 10% human AB serum, 2
mM L-glutamine, 25 mM Hepes buffer, and 100 units of
penicillin and 100 ,g of streptomycin, sulfate per ml. Cells
were cultured (105 cells per well) in 96-well round-bottomed
microtiter plates (Nunc, Intermed, Kanstrup, Denmark) for
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5 days at 37°C in humidified air with 5% CO2. Quadruplicate
cultures were exposed to medium only or to 25 1Ld of LSR2
antigen particles (undiluted or diluted 1:2.5, 1:5, or 1:10),
NCP particles alone (diluted 1:5), l3-galactosidase-blotted
NCP particles (diluted 1:2.5 or 1:5), or integral M. leprae (5
x 106 bacteria). [methyl-3H]Thymidine (2 Ci/mmol, Amer-
sham; 1 Ci = 37 GBq) was added (1 ,uCi per well) and the cells
were harvested 16 hr later. Incorporation of [3H]thymidine
was expressed as cpm (counts per minute). For cultures
stimulated with the integral M. leprae antigen, Acpm was
calculated as mean cpm of M. leprae-stimulated cultures -
mean cpm of unstimulated PBMCs. For recombinant LSR2
antigen-stimulated cultures, Acpm was calculated as mean
cpm of LSR2-stimulated cultures - mean cpm of,-galacto-
sidase-stimulated cultures.
Antibody Assays. Sera from 11 healthy contacts and from
38 TT-BT, 9 BB, and 34 BL-LL patients were depleted of
anti-E. coli antibodies and tested in a dot ELISA to detect
antibodies to LSR2 protein. Samples (2 ,ul) containing 0.4-1.6
,ug of total protein from lysates of uninduced LSR2, induced
LSR2, or induced Agtll (producing f3-galactosidase, negative
control) lysogens or 10 and 20 ng ofleprosin (positive control)
were dotted on NCP. Sera from healthy contacts and TT-BT
patients were used at dilutions of 1:25 to 1:200; sera from
BL-LL patients were tested at 1:150 and 1:300. Sera were
considered positive when an unequivocal color reaction
developed in the concentration range of the LSR2 protein
used.
DNA Sequence Analysis. DNAs from clones LSR1 and -2
were prepared by standard methods and cloned separately
into pBluescript (Stratagene) (17). The insert DNA was
isolated on low-melting-point agarose after digestion with
EcoRI. The EcoRI fragment from LSR1 and the smaller
EcoRI-Pst I fragment from LSR2 were subcloned into
M13mpl8 or M13mpl9 (Bethesda Research Laboratories) as
suggested by the supplier. DNA sequence was determined in
both directions by the dideoxy chain-termination method (20)
using universal primers. Band compressions due to second-
ary structures were resolved using Taq polymerase (Seque-
nase, United States Biochemical) and the primer extension
method. Sequence data were analyzed using IBI/Pustell
sequence-analysis programs and the amino acid sequence
was inferred.
Statistical Analysis. The correlation coefficient for optimal
responses to M. leprae and LSR2 protein was estimated by
Spearman's rank correlation (21).
RESULTS
Recombinant Protein from M. leprae DNA Expression Li-
brary. Approximately 300,000 phages of a Agtll M. leprae
DNA expression library were screened with pooled pread-
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FIG. 1. Immunoblot analysis of recombinant proteins from clones LSR1, -2, -4, and -5, showing reactivity to both polyvalent sera from LL
leprosy patients (A) and mAb to 13-galactosidase (B). Lysates from induced (lanes a) and uninduced (lanes b) lysogens of recombinants were
tested. The fusion protein bands for all four clones were at 135 kDa and were detected only in induced lysates. In B, the Bgal lanes contained
lysate from induced Agtll vector in E. coli Y1089 (lane a) or commercial ,-galactosidase marker (lane b). The second band inB indicates reactivity
with degraded fusion proteins.
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sorbed LL sera selected on the basis of high antibody levels
to sonicated M. leprae. Four clones (LSR1, -2, -4, and -5)
were identified. In contrast, pooled sera from TT patients
failed to give unequivocal signals. All four clones produced
a 135-kDa protein that reacted with LL sera (Fig. 1A) but not
with pooled sera from TT patients or with mAbs directed
against 65- and 18-kDa antigens of M. leprae. That these sera
and mAbs were immunoreactive was indicated by positive
reaction with the appropriate controls in a dot ELISA (Table
1). The 135-kDa protein reacted with a mAb directed against
13-galactosidase (Fig. 1B) and was present only in induced
cultures (lanes a), indicating that it was a fusion protein.
EcoRI digestion ofLSR1 DNA yielded an insert of800 base
pairs (bp) whereas LSR2, -4, and -5 had inserts of about 2.8
kilobase pairs (kb) (Fig. 2B). The nick-translated EcoRI
fragment from LSR2 hybridized strongly with phage DNA
from all four clones (Fig. 2A). It did not hybridize with DNA
from the control Agtll or with the five earlier reported clones
identified with murine mAbs (4). The protein from LSR2 was
investigated further for its biological relevance in cellular and
humoral responses of leprosy patients.
Lymphoproliferative Responses to the Recombinant LSR2
Protein. Since protective immunity in leprosy is associated
with cell-mediated immune responses, we examined the
ability of LSR2 protein to induce proliferation of PBMCs
from all clinical types of leprosy patients during the natural
course of M. leprae infection. Healthy laboratory personnel
with >3 years of constant exposure to patients were also
studied. For each individual, the response to the native
integral M. leprae at a predetermined concentration was
compared with the proliferation induced by the recombinant
antigen-bearing NCP particles.
Fig. 3 indicates the overall data obtained on 33 leprosy
patients and 8 healthy contacts. A striking similarity in the
pattern of responses was observed between the native and
the recombinant antigens. In general, PBMCs from healthy
subjects and BT-TT patients showed optimal [3H]thymidine
incorporation in response to both antigens (>2000 cpm).
Though individual dose responses were variable, the major
response to the native M. leprae appeared to be contributed
by the LSR2 protein. PBMC cultures from a few individuals
did not respond to the native M. leprae but showed a low
proliferative response with LSR2 antigen. In contrast, BB
and BL-LL showed low to nil responses with both antigens.
When the Acpm values obtained in all subjects with both
antigens were compared by Spearman's rank correlation, a
highly significant (P < 0.001) correlation coefficient of 0.64
was obtained. A few responder individuals who were con-
currently tested with LSR1 lysates showed responses similar
to those with LSR2 antigen (data not shown).
Antibody Responses to the Recombinant LSR2 Protein. The
percentage of individuals showing antibodies to LSR2 in-
Table 1. Reactivity of recombinant clones with mAbs and pooled
LL sera
M. leprae Specificity
mAb or antigen, for Y3178 Y3179
serum kDa M. leprae (65 kDa) (18 kDa) Agtll LSR
MC 2404 65 S + - - -
MC 0401 65 CR + + - -
MC 1723 68 S + - - -
MC 4243 65 S + - - -
MC 4220 68 CR + - - -
MC 2009 35-70 CR + - - -
SA2 D7C 65 CR + - - -
MC 8026 18 S - + - -
LL serum - - - - - +
S, specific; CR, crossreactive. For Y3178 and Y3179, see ref. 4; for
LSR clones 1, 2, 4, and 5, refer to this paper.
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FIG. 2. (A) Hybridization of [a-32PldATP-labeled EcoRI insert
from clone LSR2 to phage DNA from clones identified with murine
mAbs to M. leprae antigens of defined molecular mass [1, Y3164 (28
kDa); 2, Y3178 (65 kDa); 3, Y3179 (18 kDa); 4, Y3180 (36 kDa); 5,
Y3184 (12 kDa)], from LSR clones (6, LSR1; 7, LSR2; 8, LSR4; 9,
LSR5), and from phage Agt11 without insert (spot 10). Positive
signals were unique to LSR clones. (B) Southern blot of LSR clones
hybridized with the same probe as in A, showing EcoRI fragments of
0.8 kb for LSR1 (lane 9) and 2.8 kb for LSR2, -4, and -5 (lanes 8, 7,
and 6, respectively). Lanes 1-5 and 10 are numbered as in A and do
not show hybridization.
creased from the TT to the LL pole. Only 2 of 11 healthy
contacts had detectable levels of LSR2 antibodies (Fig. 4).
Thus it appears that in leprosy patients the pattern of anti-
body response to the recombinant protein closely follows that
observed with sonicated native M. leprae.
DNA Sequence Analysis. To further define the LSR clones
insert DNA from the LSR1 and LSR2 clones was sequenced
according to the strategy shown in Fig. 5. An open reading
20
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FIG. 3. Lymphoproliferative responses of PBMCs from 8 healthy
contacts and 33 leprosy patients to integral M. leprae (0) and
immobilized LSR2 antigen particles (e). The healthy contacts (HC)
and TT-BT patients showed positive lymphoproliferative responses
to both antigens. The multibacillary BB and BL-LL patients showed
poor or nil responses to both antigens. For both antigens Acpm was
calculated as described in Materials and Methods.
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FIG. 4. Individual sera from 11 healthy contacts (HC) and 81 leprosy patients assessed for presence of anti-LSR2 protein antibodies (hatched
bars) and anti-M. leprae antibodies (solid bars) in a dot ELISA. The relative proportion of patients showing antibodies to both antigens increased
from the TT-BT to the BL-LL pole. Fifty percent or more of the patients showing anti-M. leprae antibodies were positive for LSR2 antibodies.
Concentrations of antigens and controls used are described in Materials and Methods.
frame extending from the EcoRI site was found that coded for
the same 89 amino acids in both clones (Fig. 6), indicating
thereby that this open reading frame corresponds to the
fusion protein. The calculated size of the protein from the
predicted amino acid sequence was 9810.280 Da (-10 kDa),
with an isoelectric point of 12.17. The predicted restriction
map is shown in Fig. 5. The hydropathy plot (22) of the
protein sequence showed hydrophobic and possible amphi-
pathic regions. No significant homology was found up to
September 1990 with sequences stored in the GenBank,
National Biomedical Research Foundation, National Insti-
tute for Medical Research (Mill Hill, London) data bases
(courtesy of J. Colston).
DISCUSSION
With a view to identifying the dominant protein antigens
recognized by the human immune response to natural M.
leprae infection, we used preadsorbed polyvalent sera from
LL patients to screen the Agtll DNA expression library ofM.
leprae. Four clones were identified that coded for a lacZ
promoter-dependent fusion protein of the same molecular
mass. Clone LSR1 had an 800-bp insert, whereas the other
clones had inserts of about 2.8 kb. With the LSR2 insert as
a probe, hybridization was shown to be uniquely restricted to
LSR clones, with no detectable homology to phage DNA
derived from the five previously reported clones identified by
murine antibodies (4, 13). That the recombinant protein does
not correspond to any of the known stress proteins is
indicated by the hybridization data.
To evaluate the immunoreactivity of the fusion protein,
lysates from clone LSR2 were tested in lymphoproliferation
assays using PBMCs from patients across the leprosy spec-
trum as well as control healthy responders who had been
exposed to M. leprae. Significantly, there was marked sim-
ilarity in the lymphoproliferative responses to the fusion
protein and the native integral bacilli both at the individual
level and for the clinical type of leprosy. Maximal lym-
phoproliferative responses were observed for the healthy and
BT-TT leprosy subjects, with a marked decline in respon-
siveness for the BB and BL-LL patients. Most of the prolif-
Y
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FIG. 5. Restriction map of clones LSR1 and -2. Hatched bar represents the coding region. Length and direction of sequenced restriction
fragments are illustrated by the arrows.
BL-LL (34)
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GAATTCGGGCTTGACGGGGTGACCTACGAGATCGACCTTACGAACAAGAATGCCGCGAAA 60
GluPheGlyLeuAspGlyValThrTyrGluIleAspLeuThrAsnLysAsnAlaAlaLys
CTGCGTGGCGATCTGAGGCAATGGGTGTCCGCCG.;ACGGCGCGTCGGCGGTCGGCGGCGA 120
LeuArgGlyAspLeuArgGlnTrpValSerAlaGlyArgArgValGlyGlyArgArgArg
GGGCGTTCCAATTCTGGACGCGGCCGTGGGGCGATCGATCGCGAACAGAGCGCGGCGATC 180
GlyArgSerAsnSerGlyArgGlyArgGlyAlaIleAspArgGluGlnSerAlaAlaIle
CGGGAATGGGCTCGTCGGAACGGACATAATGTGTCGACTCGTGGTCGTATTCCGGCCGAC 240
ArgGluTrpAlaArgArgAsnGlyHisAsnValSerThrArgGlyArgIleProAlaAsp
GTCATTGACGCATTCCACGCGGCGACTTAAAATAAAAAGTTCTGTACTGACGCCCGGGCT 300
ValIleAspAlaPheHisAlaAlaThr+++
CTAGGACCCGGGCGTCAGTACTTTAAAAAAATATGTTGCTTTCGTTGCTGGCGAACTGAT 360
FIG. 6. Nucleotide and deduced amino acid sequence of the
coding region of clone LSR2, numbered from the codon commencing
from the EcoRI site. The first in-frame stop codon is indicated
(+ + +). The nucleotide sequence of clone LSR1 was identical.
erative response observed with the native antigen appears to
be contributed by the antigen represented in the fusion
protein.
Previous studies on recombinant proteins from the same
library had used T-cell lines and clones to study immuno-
reactivity (9, 23, 24). These may not truly reflect the antigens
relevant to the biology of the disease or the total T-cell
repertoire, since not all T cells may have survived the in vitro
selection pressures inherent in the current methodologies.
Similar to the present report, Dockrell et al. (10) also used
unfractionated PBMCs of leprosy patients and healthy con-
tacts for studying T-cell responses to another recombinant
protein of M. leprae, which has been shown to be an 18-kDa
stress protein. They found that 50% of tuberculoid patients
and 95% of healthy contacts showed lymphoproliferation to
this antigen. Our LSR2 protein stimulated lymphoprolifera-
tion of a higher proportion (90%) of BT-TT patients and
healthy contacts.
In antibody assays the LSR2 protein was recognized by
only half of the leprosy patient sera having detectable levels
ofantibodies to sonicated M. leprae. However, the pattern of
reactivity in the clinical groups was similar for both antigens
in that the number of patients with antibodies was lowest at
the Ti pole and increased towards the LL pole. Though the
recombinant protein had been selected on the basis of reac-
tivity with pooled LL sera having mycobacterial antibodies,
at the individual patient level the reactivity was limited. This
suggests that the humoral response to LSR2 may reflect
individual variation in antibody profiles. Alternatively, the
sonicated antigen is likely to have a larger number of epitopes
of both specific and crossreactive types. The lower-than-
expected antibody reactivity in patients appears to be com-
mon to many recombinant proteins of M. leprae (25, 26).
In both the LSR1 and the LSR2 clone, an open reading
frame extending from the EcoRI site was identified that
coded for 89 amino acids with a calculated molecular mass of
-10 kDa. With the 114 kDa for the truncated P-galactosidase
encoded in Agt11, the fusion protein would be 124 kDa.
Within the limitations in estimating molecular mass from
mobilities in SDS/polyacrylamide gels, this compares well
with 135-kDa fusion protein detected in the Western blots.
The nature ofthe gene coding for this protein is not known,
as a search in the sequence banks did not reveal significant
homology with any known gene or protein, including the 18-,
28-, 36-, 65-, and 70-kDa protein identified recently (8,
27-30). It does not appear to have sequences reminiscent of
signal peptides (31), nor does it share homology with the
28-kDa recombinant protein identified by Cherayil and
Young (32) using lepromatous sera. Sathish et al. (33) re-
cently detected 45 recombinant clones with leprosy patients
sera whose further characterization is awaited.
The recombinant protein identified by us mimics the native
M. leprae in T-cell responses across the leprosy spectrum.
Such mimicry would be amenable to exploitation for under-
standing the protective immune mechanisms in leprosy.
Moreover, the responder individuals showing T-cell reactiv-
ity to LSR2 protein were unrelated, indicating that major
histocompatibility complex (MHC) restriction did not apply
to the molecule as a whole. Such permissive MHC associa-
tion has been reported for malarial peptides (34) and may be
ofadvantage in designing vaccines. It appears that polyvalent
sera from patients are useful for identifying recombinant
proteins of relevance to human T-cell responses.
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